ArticleActa Cardiologica Sinica2018
Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Acta Cardiologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Trial
- Comparative Efficacy of Aldosterone-Related Sodium-Retention Pathway Therapies for Resistant Hypertension: A Drug-Level Network Meta-Analysis of Randomized Controlled Trials.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Article
- The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial.Cardiology research and practice · 2021Article
- Prevalence, Treatment, Control and Monitoring of Hypertension: A Nationwide Community-Based Survey in Taiwan, 2017.Acta Cardiologica Sinica · 2020Article
- Immediate Results and Long-Term Outcomes Following Percutaneous Radiofrequency Ablation of Unilateral Aldosterone-Producing Adenoma.Acta Cardiologica Sinica · 2020Article
- Association of coronary artery dominance and mortality rate and complications in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020Article
- Gabapentin Reduces Blood Pressure and Heart Rate through the Nucleus Tractus Solitarii.Acta Cardiologica Sinica · 2019Article
- From Real-World Evidence to Consensus of Renal Denervation in Taiwan: A Call for the Incorporation of Ambulatory Blood Pressure Monitoring after Witnessed Intake of Medications.Acta Cardiologica Sinica · 2019Article
- Efficacy and Safety of Renal Denervation for Patients with Uncontrolled Hypertension in Taiwan: 3-Year Results From the Global SYMPLICITY Registry-Taiwan (GSR-Taiwan).Acta Cardiologica Sinica · 2019Article
- 2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension.Acta Cardiologica Sinica · 2019Review
- Effect of Radiofrequency-Based Renal Denervation: The Impact of Unplanned Medication Change from a Systematic Review and Meta-Analysis.Acta Cardiologica Sinica · 2019Article
- Spironolactone Use to Treat Hypertension: in the Right Patient Groups at the Right Time.Acta Cardiologica Sinica · 2018Article
- Spironolactone Monotherapy in Special Population of Patients with Hypertension.Acta Cardiologica Sinica · 2018Article
- Our Stance towards the 2017 ACC/AHA High Blood Pressure Clinical Practice Guideline: Has the Pendulum Swung Too Far?Acta Cardiologica Sinica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh blood pressure (BP) is a common chronic disease needs long life drug consumption to control. Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension. However, there is no study to determine the effects of low dose spironolactone as a first line therapy in treatment of essential hypertension. The aim of this study is to investigate the effect of low dose spironolactone monotherapy in management of essential hypertension.
methodsIn this double blind randomized clinical trial, 40 patients who had stage I essential hypertension were randomly divided into two groups: intervention group received spironolactone 25 milligram once daily for one month and control group received placebo once daily. At the baseline and after one month, 24-hour BP holter-monitoring and serum potassium assay were done.
resultsSystolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004). There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
conclusionsShort course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.